Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: Safety, tolerability and adherence

HIV Medicine

Volumn 15, Issue 1, 2014, Pages 13-22

  Mcallister, J ^a   Read, P ^b,c   Mcnulty, A ^b,d   Tong, Wwy ^a   Ingersoll, A ^a   Carr, A ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b SYDNEY EYE HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

HIV; Post exposure prophylaxis; Raltegravir

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUDESONIDE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMTRICITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPNOTIC AGENT; ILLICIT DRUG; METHAMPHETAMINE; OPIATE DERIVATIVE; PHENYTOIN; PHOSPHODIESTERASE V INHIBITOR; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; RALTEGRAVIR; SILDENAFIL; STAVUDINE; TENOFOVIR; VARDENAFIL;

ABDOMINAL CRAMP; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL INTOLERANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOATING; COHORT ANALYSIS; CONCENTRATION LOSS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DEPRESSION; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLATULENCE; HEADACHE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPERTRANSAMINASEMIA; HYPOPHOSPHATEMIA; INCREASED APPETITE; INSOMNIA; INTENTION TO TREAT ANALYSIS; LACTATE BLOOD LEVEL; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MEN WHO HAVE SEX WITH MEN; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NONOCCUPATIONAL POST EXPOSURE PROPHYLAXIS; OPEN STUDY; PARESTHESIA; PHARYNGITIS; POST EXPOSURE PROPHYLAXIS; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RHABDOMYOLYSIS; SIDE EFFECT; SWEATING; THIRST; TREATMENT DURATION; VIVID DREAM;

HIV; POST-EXPOSURE PROPHYLAXIS; RALTEGRAVIR;

ADENINE; ADULT; ANTI-HIV AGENTS; BIOLOGICAL MARKERS; CREATINE KINASE; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; MEDICATION ADHERENCE; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; PYRROLIDINONES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84888879920     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12075     Document Type: Article

References (33)

1. Panlilio AL, Cardo DM, Grohskopf LA, Heneine W, Ross CL. Updated U.S. Public Health Service guidelines for the management of occupational exposure to HIV and recommendations for postexposure prophylaxis. MMWR Morb Mortal Wkly Rep 2005; 54 (RR09): 1-17.
2. Smith DK, Grohskopf LA, Black RJ etal. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States. MMWR Morb Mortal Wkly Rep 2005; 54 (RR02): 1-20.
3. Benn P, Fisher M, Kulasegaram R, on behalf of the BASHH PEPSE Guidelines Writing Group. UK guideline for the use of post exposure prophylaxis for HIV following sexual exposure. Int J STD AIDS 2011; 22: 695-708.
4. NPEP Reference Group. Australian national guidelines for post-exposure prophylaxis after non-occupational exposure to HIV (draft). Available at www.ashm.org.au/ (accessed 26 April 2013).
5. Tsai C-C, Follis KE, Sabo A etal. Prevention of SIV infection in macaques by (R)-9-(2-Phosphonylmethoxypropyl) adenine. Science 1995; 270: 1197-1199.
6. Connor EM, Sperling RS, Gelber R etal. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-1180.
7. Cardo DM, Culver DH, Ciesielski CA etal. A case-control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med 1997; 337: 1485-1490.
8. Grant RM, Lama JR, Anderson PL etal. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363: 2587-2599.
9. Cohen MS, Chen YQ, McCauley M etal. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365: 493-505.
10. Le Grand R, Vaslin B, Larghero J etal. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. AIDS 2000; 14: 1864-1866.
11. Jochimsen EM, Luo CC, Beltrami JF, Respess RA, Schable CA, Cardo DM. Investigations of possible failures of postexposure prophylaxis following occupational exposures to human immunodeficiency virus. Arch Intern Med 1999; 159: 2361-2363.
12. Roland ME, Neilands TB, Krone M etal. Seroconversion following nonoccupational postexposure prophylaxis against HIV. Clin Infect Dis 2005; 41: 1507-1513.
13. Rabaud C, Bevilacqua S, Beguinot I etal. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 1494-1495.
14. Rabaud C, Burty C, Grandidier M etal. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. Clin Infect Dis 2005; 40: 303-305.
15. Burty C, Pavel S, Ghomari K etal. Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection. J Acquir Immune Defic Syndr 2008; 49: 334-336.
16. Tosini W, Muller P, Prazuk T etal. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS 2010; 24: 2375-2380.
17. Diaz-Brito V, Leon A, Knobel H etal. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther 2012; 17: 337-346.
18. Winston A, McAllister J, Amin J, Cooper DA, Carr A. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV postexposure prophylaxis. HIV Med 2005; 6: 191-197.
19. Mayer K, Mimiaga MJ, Cohen D etal. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston community health centre. J Acquir Immune Defic Syndr 2008; 47: 494-499.
20. Steigbigel RT, Cooper DA, Kumar PN etal. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359: 339-354.
21. Markowitz M, Nguyen B-Y, Gotuzzo E etal. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-Week controlled study. J Acquir Immune Defic Syndr 2007; 46: 125-133.
22. Gotuzzo E, Markowitz M, Ratanasuwan W etal. Sustained efficacy and safety of raltegravir after 5 years of combination antiretroviral therapy as initial treatment of HIV-1 infection: final results of a randomized controlled phase II study (protocol 004). J Acquir Immune Defic Syndr 2012; 61: 73-77.
23. Lee FJ, Amin J, Bloch M, Pett SL, Marriott D, Carr A. Skeletal muscle toxicity associated with raltegravir-based combination anti-retroviral therapy in HIV-infected adults. J Acquir Immune Defic Syndr 2013; 62: 525-533.
24. Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, Tenofovir DF and Emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability and adherence. J Acquir Immune Defic Syndr 2012; 59: 354-359.
25. Australasian Society for HIV Medicine. HSS Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents (2012). Available at www.ashm.org.au/ (accessed 26 April 2013).
26. National Institute of Allergy and Infectious Diseases, Division of AIDS. Table for grading the severity of adult and pediatric adverse events version 1.0 (clarification August 2009) (2004). Available at http://rsc.tech-res.com/safetyandpharmacovigilance/gradingtables.aspx (accessed 31 August 2013).
27. NPEP Reference Group. Australian national guidelines for post-exposure prophylaxis after nonoccupational exposure to HIV. Sex Health 2007; 4: 277-283.
28. New York State Department of Health AIDS Institute. HIV prophylaxis following occupational exposure. Available at www.hivguidelines.org/clinical-guidelines/post-exposure-prophylaxis/hiv-prophylaxis-following-occupational-exposure/ (accessed 26 April 2013).
29. Gruber VA, McCance-Katz EF. Methadone, Buprenorphine, and street drugs interactions with antiretroviral medication. Curr HIV/AIDS Rep 2010; 7: 152-160.
30. Henry JA, Hill IR. Fatal reaction between ritonavir and MDMA. Lancet 1998; 28: 1751-1752.
31. Harrington RD, Woodward JA, Hooton TM, Horn JL. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999; 159: 2221-2224.
32. Rudd P, Byyny RL, Zachary V etal. The natural history of medication compliance in a drug trial: limitations of pill counts. Clin Pharmacol Ther 1989; 46: 169-176.
33. Liu H, Golin CE, Miller LG etal. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 2001; a34: 968-977.